Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.

Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, Cornell RF.

Clin Lymphoma Myeloma Leuk. 2018 Mar 14. pii: S2152-2650(17)31881-5. doi: 10.1016/j.clml.2018.03.003. [Epub ahead of print] Review.

PMID:
29610030
2.

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.

Neggers JE, Kwanten B, Dierckx T, Noguchi H, Voet A, Bral L, Minner K, Massant B, Kint N, Delforge M, Vercruysse T, Baloglu E, Senapedis W, Jacquemyn M, Daelemans D.

Nat Commun. 2018 Feb 5;9(1):502. doi: 10.1038/s41467-017-02349-8.

3.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

4.

Decrypting the PAK4 transcriptome profile in mammary tumor forming cells using Next Generation Sequencing.

Rane CK, Patel M, Cai L, Senapedis W, Baloglu E, Minden A.

Genomics. 2017 Oct 18. pii: S0888-7543(17)30128-3. doi: 10.1016/j.ygeno.2017.10.004. [Epub ahead of print]

5.

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.

Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, Baloglu E, Müschen M, Koeffler HP.

Leukemia. 2018 Mar;32(3):616-625. doi: 10.1038/leu.2017.281. Epub 2017 Sep 14.

PMID:
28904384
6.

Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

Small GTPases. 2017 Jun 22:0. doi: 10.1080/21541248.2017.1329694. [Epub ahead of print]

PMID:
28641032
7.

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.

Hwang VJ, Zhou X, Chen X, Trott J, Abu Aboud O, Shim K, Dionne LK, Chmiel KJ, Senapedis W, Baloglu E, Mahjoub MR, Li X, Weiss RH.

Kidney Int. 2017 Oct;92(4):922-933. doi: 10.1016/j.kint.2017.03.031. Epub 2017 May 23.

PMID:
28545714
8.

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.

Rane C, Senapedis W, Baloglu E, Landesman Y, Crochiere M, Das-Gupta S, Minden A.

Sci Rep. 2017 Feb 15;7:42555. doi: 10.1038/srep42555.

9.

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC.

Blood. 2017 Apr 20;129(16):2233-2245. doi: 10.1182/blood-2016-06-724831. Epub 2017 Jan 17.

10.

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.

11.

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.

Vercruysse T, De Bie J, Neggers JE, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D.

Clin Cancer Res. 2017 May 15;23(10):2528-2541. doi: 10.1158/1078-0432.CCR-16-1580. Epub 2016 Oct 25.

PMID:
27780859
12.

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM.

Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.

13.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.

14.

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.

Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA.

Nature. 2016 Oct 6;538(7623):114-117. doi: 10.1038/nature19771. Epub 2016 Sep 28.

15.

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH.

Mol Cancer Ther. 2016 Sep;15(9):2119-29. doi: 10.1158/1535-7163.MCT-16-0197. Epub 2016 Jul 7.

16.

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.

Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT.

Leukemia. 2017 Jan;31(1):143-150. doi: 10.1038/leu.2016.145. Epub 2016 May 23.

17.

Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.

Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Senapedis W, Baloglu E, Kanojia D, Shang L, Xu X, Yang H, Tyner JW, Wang MR, Koeffler HP.

Gut. 2017 Aug;66(8):1358-1368. doi: 10.1136/gutjnl-2016-311818. Epub 2016 May 10.

PMID:
27196599
18.

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.

Taylor-Kashton C, Lichtensztejn D, Baloglu E, Senapedis W, Shacham S, Kauffman MG, Kotb R, Mai S.

J Cell Physiol. 2016 Dec;231(12):2711-9. doi: 10.1002/jcp.25378. Epub 2016 Apr 8.

19.

XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.

Ferreiro-Neira I, Torres NE, Liesenfeld LF, Chan CH, Penson T, Landesman Y, Senapedis W, Shacham S, Hong TS, Cusack JC.

Clin Cancer Res. 2016 Apr 1;22(7):1663-73. doi: 10.1158/1078-0432.CCR-15-0978. Epub 2015 Nov 24.

20.

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Crochiere M, Kashyap T, Kalid O, Shechter S, Klebanov B, Senapedis W, Saint-Martin JR, Landesman Y.

BMC Cancer. 2015 Nov 17;15:910. doi: 10.1186/s12885-015-1790-z.

21.

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM.

Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

22.

Therapeutic Potential of Targeting PAK Signaling.

Senapedis W, Crochiere M, Baloglu E, Landesman Y.

Anticancer Agents Med Chem. 2016;16(1):75-88. Review.

PMID:
26081410
23.

Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C.

J Hematol Oncol. 2014 Dec 5;7:85. doi: 10.1186/s13045-014-0085-1. Review.

24.

Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.

Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB.

PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014.

25.

Clinical translation of nuclear export inhibitors in cancer.

Senapedis WT, Baloglu E, Landesman Y.

Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19. Review.

PMID:
24755012
26.

CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.

Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC.

Mol Cancer Ther. 2013 Jul;12(7):1171-9. doi: 10.1158/1535-7163.MCT-12-1171. Epub 2013 Apr 24.

27.

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC.

Leukemia. 2014 Jan;28(1):155-65. doi: 10.1038/leu.2013.115. Epub 2013 Apr 16.

28.

Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain.

Senapedis WT, Kennedy CJ, Boyle PM, Silver PA.

Mol Biol Cell. 2011 May 15;22(10):1791-805. doi: 10.1091/mbc.E10-10-0854. Epub 2011 Apr 1.

29.

A structurally tunable DNA-based extracellular matrix.

Aldaye FA, Senapedis WT, Silver PA, Way JC.

J Am Chem Soc. 2010 Oct 27;132(42):14727-9. doi: 10.1021/ja105431h.

30.

TACC3-TSC2 maintains nuclear envelope structure and controls cell division.

Gómez-Baldó L, Schmidt S, Maxwell CA, Bonifaci N, Gabaldón T, Vidalain PO, Senapedis W, Kletke A, Rosing M, Barnekow A, Rottapel R, Capellá G, Vidal M, Astrinidis A, Piekorz RP, Pujana MA.

Cell Cycle. 2010 Mar 15;9(6):1143-55. Epub 2010 Mar 15.

PMID:
20237422
31.

Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner.

Astrinidis A, Senapedis W, Henske EP.

Hum Mol Genet. 2006 Jan 15;15(2):287-97. Epub 2005 Dec 8.

PMID:
16339216
32.

Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B.

Astrinidis A, Senapedis W, Coleman TR, Henske EP.

J Biol Chem. 2003 Dec 19;278(51):51372-9. Epub 2003 Oct 9.

33.

Expression of wild type and mutant TSC2, but not TSC1, causes an increase in the G1 fraction of the cell cycle in HEK293 cells.

Khare L, Astrinidis A, Senapedis W, Adams PD, Henske EP.

J Med Genet. 2002 Sep;39(9):676-80. No abstract available.

Supplemental Content

Loading ...
Support Center